WallStreetZen

NYSE: NVO
Novo Nordisk A S Earnings & Revenue

NVO past earnings growth

How has NVO's earnings growth performed historically?
Company
16.41%
Industry
23.72%
Market
102.72%
NVO's earnings have grown slower (7.48% per year) than the US Biotechnology industry average (17.24%)
Performance
NVO's earnings have grown slower (7.48% per year) than the US market average (27.52%)
Performance
NVO's earnings growth is accelerating - its growth over the last year (16.41%) is above its 5-year compound annual rate (7.48%)
Performance

NVO past revenue growth

How has NVO's revenue growth performed historically?
Company
8.17%
Industry
787.63%
Market
36.32%
NVO's revenue has grown slower (3.87% per year) than the US Biotechnology industry average (141.8%)
Performance
NVO's revenue has grown slower (3.87% per year) than the US market average (17.66%)
Performance
NVO's revenue growth is accelerating - its growth over the last year (8.17%) is above its 5-year compound annual rate (3.87%)
Performance

NVO earnings and revenue history

Current Revenue
$20.1B
Current Earnings
$6.8B
Current Profit Margin
33.8%

NVO Return on equity

Current Company
71%
Current Industry
-34.7%
Current Market
30.7%
NVO's Return on Equity (71%) shows a company that is highly efficient at transforming shareholder equity into returns
Performance

NVO Return on assets

Current Company
30.5%
Current Industry
-9.4%
Current Market
6.4%
NVO is generating higher Return on Assets (30.5%) than the US Biotechnology industry average (-5.92%)
Performance

NVO Return on capital employed

Current Company
81.4%
Current Industry
3.9%

Novo Nordisk A S Earnings & Revenue FAQ

What were NVO's earnings last quarter?

Novo Nordisk A S (NYSE: NVO) reported Q1 2021 earnings per share (EPS) of $0.87, up 16.35% year over year. Total Novo Nordisk A S earnings for the quarter were $2.00 billion. In the same quarter last year, Novo Nordisk A S's earnings per share (EPS) was $0.75.

What was NVO's earnings growth in the past year?

As of Q3 2021, Novo Nordisk A S's earnings has grown 16.41% year over year. This is 7.31 percentage points lower than the US Biotechnology industry earnings growth rate of 23.72%. Novo Nordisk A S's earnings in the past year totalled $6.91 billion.

What was NVO's revenue last quarter?

Novo Nordisk A S (NYSE: NVO) reported Q1 2021 revenue of $5.37 billion up 7.71% year over year. In the same quarter last year, Novo Nordisk A S's revenue was $4.98 billion.

What was NVO's revenue growth in the past year?

As of Q3 2021, Novo Nordisk A S's revenue has grown 8.17% year over year. This is 779.46 percentage points lower than the US Biotechnology industry revenue growth rate of 787.63%. Novo Nordisk A S's revenue in the past year totalled $20.46 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.